Study says DPP-IV benefits may go beyond diabetes

Share this article:

DPP-IV diabetes medications may have benefits beyond insulin control. PharmaTimes reports that a Brigham and Women's Hospital study shows the medications may be associated with a reduced risk of autoimmune diseases among type-2 diabetics. PT says researcher Seoyoung Kim told reporters at the American College of Rheumatology conference that diabetics taking DPP-IV combination therapy were 34% less likely to develop RA and reduced their risk of other autoimmune diseases by 27%.

PT notes that the study is not definitive, but further evidence would benefit Merck's Januvia (which has seen sales slide) and the Boehringer Ingelheim/Eli Lilly drug Tradjenta. The DPP-IV class also includes the Bristol-Myers Squibb/AstraZeneca drug Onglyza.

The diabetes category as a whole is getting tighter. Merck noted in its conference call, for example, that "the DPP-IV market and branded worldwide diabetic market isn't growing." Additional pressures, such as being squeezed out of PBM formulary offerings have added to category pressures.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions